TWST News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TW

Mkt Cap

$8.81B

Volume

2.55M

Next Earnings

November 13th

Loading chart

TW

TWSTTwist Bioscience Corporation Common Stock

TWST

Pay with—

Available Balance0.00

TW

Mkt Cap

$9.58B

Volume

2.55M

Next Earnings

November 13th

Chart Financials Earnings News About Insider Filings

Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCelleraThe global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.GlobeNewswire Inc. · Oct 12, 2026

Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion OpportunityThe global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.GlobeNewswire Inc. · Oct 5, 2026

Why Twist Bioscience Stock Skyrocketed This WeekTwist Bioscience stock surged over 31% this week after announcing a partnership with Eli Lilly to participate in Lilly TuneLab, an AI-powered drug discovery initiative. Twist will provide antibody characterization data services and leverage its AbLab model, generating revenue while contributing to and benefiting from the advanced research platform.The Motley Fool · Sep 18, 2026

Cathie Wood Is Selling This High-Flying Stock. Is It a Buy?Cathie Wood's Ark ETFs sold over $11 million worth of Twist Bioscience stock on June 30, 2026, despite the synthetic DNA manufacturer's stock climbing 190% year-to-date. The sales appear to be portfolio rebalancing rather than a loss of confidence, as Ark still holds over $332 million in Twist across its ETFs. The proceeds were used to purchase stakes in other companies like Circle Internet Group and SoFi Technologies.The Motley Fool · Jul 19, 2026

The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to OwnThe next wave of AI adoption is shifting from tool-builders to companies applying AI in real-world drug development. Eli Lilly leverages AI partnerships with OpenAI and Nvidia for drug discovery while expanding its weight-loss portfolio, showing strong financial growth. Twist Bioscience supplies synthetic DNA for drug testing and benefits from Amazon's new Bio Discovery platform, offering higher-risk growth potential.The Motley Fool · Jun 19, 2026

ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.Benzinga · Feb 24, 2026

DNA Computing Market - Global Forecast 2025-2032The DNA computing market is projected to grow from $293.70 million in 2025 to $2.68 billion by 2032, with a 36.76% CAGR, driven by innovations in data storage, cryptography, and molecular computing technologies.GlobeNewswire Inc. · Dec 12, 2025

Cell Culture Microcarriers Market Size Leads at 8.54% CAGR by 2034 – Towards HealthcareThe global cell culture microcarriers market is projected to grow from USD 3.45 billion in 2025 to USD 7.2 billion by 2034, with an 8.54% CAGR, driven by advancements in biopharmaceuticals, cell therapies, and regenerative medicine research.GlobeNewswire Inc. · Dec 1, 2025

DNA Data Storage Market to Reach $3348 Million by 2030, Transforming the Future of Data ArchivingThe DNA data storage market is expected to grow from $76 million in 2024 to $3,348 million by 2030, with a CAGR of 87.7%. The market is driven by increasing cybersecurity concerns and the need for secure, compact data storage solutions, particularly in healthcare and biotechnology sectors.GlobeNewswire Inc. · Aug 22, 2025

Twist Bioscience (TWST) Q3 Profit SurgesTwist Bioscience reported strong Q3 results with 18% revenue growth, achieving profitability through a one-time gain and improved operational efficiency. The company saw growth in Next Generation Sequencing and strategic product launches while managing slower Synthetic Biology segment performance.The Motley Fool · Aug 4, 2025

to start trading

TW

TWSTTwist Bioscience Corporation Common Stock

TWST

Pay with—

Available Balance0.00

Your PositionYou don't own any TWST yet.

Related Tickers

Earnings